INHIBIKASE THERAPEUTICS ($IKT) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.09 per share.
You can see Quiver Quantitative's $IKT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INHIBIKASE THERAPEUTICS Insider Trading Activity
INHIBIKASE THERAPEUTICS insiders have traded $IKT stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IKT stock by insiders over the last 6 months:
- ROBERTO BELLINI purchased 1,460,000 shares for an estimated $2,000,200
- AMIT MUNSHI purchased 365,000 shares for an estimated $500,050
- ARVIND KUSH purchased 145,000 shares for an estimated $198,650
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
INHIBIKASE THERAPEUTICS Hedge Fund Activity
We have seen 30 institutional investors add shares of INHIBIKASE THERAPEUTICS stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SANDS CAPITAL VENTURES, LLC added 10,950,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $35,587,500
- SOLEUS CAPITAL MANAGEMENT, L.P. added 6,325,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,556,250
- FAIRMOUNT FUNDS MANAGEMENT LLC added 6,125,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $19,906,250
- PERCEPTIVE ADVISORS LLC added 5,925,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $19,256,250
- COMMODORE CAPITAL LP added 5,925,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $19,256,250
- ADAR1 CAPITAL MANAGEMENT, LLC added 5,103,005 shares (+inf%) to their portfolio in Q4 2024, for an estimated $16,584,766
- VANGUARD GROUP INC added 2,821,921 shares (+16873.5%) to their portfolio in Q4 2024, for an estimated $9,171,243
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
INHIBIKASE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $IKT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 11/08/2024
- H.C. Wainwright issued a "Buy" rating on 10/11/2024
To track analyst ratings and price targets for INHIBIKASE THERAPEUTICS, check out Quiver Quantitative's $IKT forecast page.
INHIBIKASE THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $IKT recently. We have seen 2 analysts offer price targets for $IKT in the last 6 months, with a median target of $6.5.
Here are some recent targets:
- Dennis Ding from Jefferies set a target price of $8.0 on 11/08/2024
- Edward White from H.C. Wainwright set a target price of $5.0 on 10/11/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
